


## Listing of Claims:

1. (Currently Amended) A compound ~~Compounds~~ of ~~general~~ formula

I



in which radicals  $R^1$ ,  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  as well as  $R^{15}$  and  $R^{16}$  have the following meaning:

- $R^1$  is a hydrogen atom, an alkanoyl radical with 1 to 10 carbon atoms or an optionally substituted benzoyl radical with 6-10 carbon atoms or a radical  $\text{CONHR}^5$ , whereby  $R^5$  is a hydrogen atom, an alkyl or acyl radical with 1-10 carbon atoms in each case or an alkylaryl or aralkyl radical with 6-10 carbon atoms in each case,
- $R^2$  is ~~a hydrogen atom~~, a halogen atom or a  $\text{CF}_3$  group,
- $R^3$  is a hydrogen atom or a group  $\text{CH}_2\text{X}$ , in which X stands for a hydrogen atom, a hydroxy group, a halogen atom, an alkyl radical with 1 or 2 carbon atoms, or X stands for a radical  $(\text{CH}_2)_n\text{CH}_2\text{Y}$  with  $n = 0$  or  $1$ , and Y stands for a halogen

atom,

whereby if

$R^2$  is a halogen atom,  $R^3$  in addition can mean a group  $C_nF_mH_o$ , whereby  $n = 1, 2,$

3, 4 or 5,  $m > 1$  and  $m + o = 2n + 1$ ,

$R^4$  means a hydrogen atom, an alkyl or alkanoyl radical that consists of 1-10 carbon atoms in each case or a benzoyl radical with 6-10 carbon atoms or a radical  $-CONHR^5$ , whereby  $R^5$  has the above-indicated meaning, and

$R^{15}$  and  $R^{16}$  represent hydrogen atoms or together a double bond,

~~whereby 4-[17 $\alpha$ -chloromethyl-17 $\beta$ -hydroxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime and 4-[17 $\alpha$ -chloromethyl-17 $\beta$ -methoxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime are excluded.~~

2. (Currently Amended) A compound ~~Compounds of general formula 1~~ according to claim 1, in which  $R^2$  is a chlorine or bromine atom.

3. (Currently Amended) A compound ~~Compounds of general formula I~~ according to claim 1, in which  $R^3$  is a hydrogen atom or a group  $CH_2X$ , in which X can be a hydrogen atom, a hydroxy group, a halogen atom, a straight-chain or branched or unsaturated alkyl radical with 1-2 ~~1-4~~ carbon atoms, a radical  $(CH_2)_nCH_2Y$  with  $n = 0$  or 1, and Y can be a halogen atom, and X and/or Y can be fluorine, chlorine or bromine.

4. (Currently Amended) A compound ~~Compounds~~ of general formula I, ~~wherein characterized in that~~  $R^4$  is a hydrogen atom or an alkyl radical with 1 to 4 carbon atoms.

5. (Currently Amended) A compound ~~Compounds~~ of general formula I according to claim 1, in which  $R^1$  means a hydrogen atom,  $R^2$  stands for a hydrogen atom, a chlorine atom or a bromine atom, and  $R^3$  can be a hydrogen atom, a methyl group, or a  $CH_2-X$  group, whereby X stands for a fluorine, chlorine or bromine atom or a hydroxy group.

6. (Currently Amended) A compound ~~Compounds~~ of general formula I, according to claim 1, which is namely:

4-[4'-Bromo-17 $\beta$ -hydroxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime,

4-[4'-Bromo-17 $\beta$ -hydroxy-17 $\alpha$ -methyl-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime,

4-[4'-Bromo-17 $\beta$ -hydroxy-17 $\alpha$ -trifluoromethyl-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime,

~~4-[17 $\alpha$ -Bromomethyl-17 $\beta$ -hydroxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime,~~

~~4-[17 $\beta$ -Hydroxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime,~~

~~4-[17 $\beta$ -Acetoxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime,~~

4-[17 $\beta$ -Acetoxy-4'-bromo-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime,  
4-[17 $\beta$ -Acetoxy-4'-bromo-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-O-  
acetyloxime,

~~4-[17 $\beta$ -Benzoyloxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime,~~  
~~4-[17 $\beta$ -(N-Ethylamino)carbonyloxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-~~  
~~(E)-oxime,~~

~~4-[17 $\beta$ -Hydroxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-[N-~~  
~~(ethylamino)carbonyl]oxime,~~

~~4-[17 $\beta$ -Methoxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-[N-~~  
~~(ethylamino)carbonyl]oxime,~~

~~4-[17 $\beta$ -Methoxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime,~~  
4-[4'-Bromo-17 $\beta$ -methoxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime,  
~~4-[17 $\beta$ -Hydroxy-3-oxoestra-4,9,15-trien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime,~~  
~~4-[17 $\beta$ -Methoxy-3-oxoestra-4,9,15-trien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime,~~  
~~4-[17 $\beta$ -Hydroxy-17 $\alpha$ -methyl-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime,~~  
4-[4'-Chloro-17 $\beta$ -hydroxy-17 $\alpha$ -trifluoromethyl-3-oxoestra-4,9-dien-11 $\beta$ -  
yl]benzaldehyde-1-(E)-oxime,

4-[4'-Chloro-17 $\beta$ -hydroxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime,  
~~4-[17 $\alpha$ -Fluoromethyl-17 $\beta$ -hydroxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-~~  
~~(E)-oxime,~~

4-[4'-Bromo-17 $\alpha$ -fluoromethyl-17 $\beta$ -hydroxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-

1-(E)-oxime,

4-[4'-Bromo-17 $\alpha$ -chloromethyl-17 $\beta$ -hydroxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-

1-(E)-oxime,

4-[4'-Bromo-17 $\alpha$ -bromomethyl-17 $\beta$ -hydroxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-

1-(E)-oxime,

4-[4'-Chloro-17 $\beta$ -methoxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime,

4-[4'-Chloro-17 $\alpha$ -chloromethyl-17 $\beta$ -hydroxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-

1-(E)-oxime,

~~4-[17 $\beta$ -Ethoxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime,~~

~~4-[17 $\beta$ -Isopropoxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime,~~

~~4-[17 $\beta$ -Benzyloxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-oxime,~~

4-[17 $\beta$ -Methoxy-4'-trifluoromethyl-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-

(E)-oxime, or

4-[4'-Chloro-17 $\beta$ -hydroxy-17 $\alpha$ -methyl-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1(E)-

oxime,

~~4-[17 $\beta$ -Hydroxy-17 $\alpha$ -methyl-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-[O-~~

~~(ethylamino)carbonyl]oxime;~~

~~4-[17 $\beta$ -Hydroxy-17 $\alpha$ -hydroxymethyl-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-[O-~~

~~(ethylamino)-carbonyl]oxime.~~

7. (Currently Amended)

A pharmaceutical composition comprising

~~Pharmaceutical preparations that contain at least one compound of general formula I according to claim 1 and as well as a pharmaceutically compatible vehicle.~~

8. (Currently Amended)      A method ~~Use of the compounds of general formula I according to one of claims 1 to 6 for the production of pharmaceutical agents for female birth control, comprising administering to a female a compound of claim 1.~~
9. (Currently Amended)      A method ~~Use of the compounds of general formula I according to one of claims 1 to 6 for the production of pharmaceutical agents for treating dysfunctional bleeding, comprising administering to a host in need thereof a compound of claim 1.~~
10. (Currently Amended)      A method ~~Use of the compounds of general formula I according to one of claims 1 to 6 for the production of pharmaceutical agents for treating a dysmenorrhea, comprising administering to a host in need thereof a compound of claim 1.~~
11. (Currently Amended)      A method ~~Use of the compounds of general formula I according to one of claims 1 to 6 for the production of pharmaceutical agents for inducing an amenorrhea, comprising administering to a host in need thereof a~~

compound of claim 1.

12. (Currently Amended)      A method ~~Use of the compounds of general formula~~  
~~I according to one of claims 1 to 6 for the production of pharmaceutical agents for~~  
~~treating hormonal disorders in postmenopausal women, comprising administering~~  
~~to a host in need thereof a compound of claim 1.~~

13. (Currently Amended)      A process ~~Use of the compounds of general formula~~  
~~I according to one of claims 1 to 6 for the production of pharmaceutical agents for~~  
~~treating endometriosis or as well as uterus myomatoses, whereby 4-[17 $\alpha$ -~~  
~~chloromethyl-17 $\beta$ -hydroxy-3-oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1-(E)-~~  
~~oxime and 4-[17 $\alpha$ -chloromethyl-17 $\beta$ -methoxy-3-oxoestra-4,9-dien-11 $\beta$ -~~  
~~yl]benzaldehyde-1-(E)-oxime are excluded comprising administering to a host in~~  
~~need thereof a compound of claim 1.~~

14. (Currently Amended)      A method ~~Use according to claim one of claims 8 to~~  
~~10, wherein the compound is administered~~ in combination with at least one low-  
dose natural or synthetic estrogen or prodrug ~~prodrugs~~ thereof.

15. (Currently Amended)      A method ~~Use according to claim 14 11, comprising~~  
~~using an wherein the estrogen as its is used as 3-sulfamate.~~

16. (Currently Amended)      A method Use according to claim 15 12, wherein  
the estrogen-3-sulfamate is 17 $\beta$ -hydroxy-estra-1,3,5(10)-trien-3yl-sulfamate.

17. (New)      A method for the production of a pharmacological agent,  
comprising bringing together a compound of claim 1 and a pharmacologically  
acceptable carrier.